“Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy With Baricitinib 4-Mg: Results From BRAVE-AA1 and -AA2 Trials”. 2025. SKIN The Journal of Cutaneous Medicine 9 (1): s522. https://doi.org/10.25251/skin.9.supp.522.